Molecular breast imaging
This article was originally published in The Gray Sheet
Executive Summary
Procedure may be a useful adjunct to mammography screens in detecting breast cancer in women at risk for the disease or with dense breasts, according to a study presented at the American Society of Clinical Oncology's annual Breast Cancer Symposium Sept. 5-7 in Washington, D.C. A 15-month follow-up of 375 women in the 940-patient trial, conducted at the Mayo Clinic in Rochester, Minn., showed that MBI had 75% sensitivity and 93.2% specificity, compared to 25% sensitivity and 91.3% specificity with mammography. The next step is to compare the technology to magnetic resonance imaging and other screening methods, lead investigator Carrie Hruska noted in a Sept. 3 press release. MBI costs more than mammography, but one-fifth less than MRI, according to the study authors
You may also be interested in...
Research In Brief
No to knee 'scoping: Arthroscopic knee surgery for osteoarthritis provides no additional benefits to optimized physical and medical therapy alone, according to the results of a Canadian study appearing in the Sept. 11 issue of the New England Journal of Medicine. Researchers at the University of Western Ontario randomized 178 patients with moderate-to-severe osteoarthritis of the knee to either surgical lavage and arthroscopic debridement plus physical and medical therapy or physical and medical therapy alone. After two years, the mean scores for both groups on the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index were almost the same: 874 for the surgery group and 897 for the control group. Analysis of the WOMAC scores and other secondary endpoints also showed no superiority for surgery. The results of this study on top of several previous studies on arthroscopic knee lavage and debridement "call into question the widespread use of arthroscopic treatment for osteoarthritis of the knee," Alexandra Kirkley et al. write. They also observe that "although some may argue that treatment is beneficial for patients with mechanical symptoms of catching or locking or those with early disease, prespecified subgroup analyses also failed to show efficacy in this population of patients.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.